SAN FRANCISCO, CA, May 07, 2015 (Marketwired via COMTEX) -- Medivation, Inc. MDVN, +0.89% today reported its financial results for the first quarter ended March 31, 2015. U.S. net sales of XTANDI(R) (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. prior year). On its February 25, 2015 earnings call, Medivation stated its expectation that first quarter U.S. net sales may be at or below fourth quarter 2014 net sales of $230.2 million. First quarter U.S. net sales of $224.0 million were driven by an increase in underlying demand (low teens percent) offset by an anticipated higher gross-to-net rate as compared with fourth quarter net sales of $230.2 million, which included an increase in channel partner inventory of approximately one week.
Help employers find you! Check out all the jobs and post your resume.
